Diazoxide, utilised in hyperinsulinism since the 1960s,1 is the recommended first-line pharmacological therapy for children with hyperinsulinism.2 It blocks the sulfonylurea receptor 1 (SUR1) subunit of KATP-channel on pancreatic beta cells, increasing the permeability to potassium ions leading to hyperpolarization of the cells and inhibition of calcium-dependent insulin secretion.3 The recently published International Guidelines for the Diagnosis and Management of Hyperinsulinism2 recommends...
